West Pharmaceutical's Q4 Performance Surpass Expectations, Expects FY22 Sales To Increase 8%

Comments
Loading...

West Pharmaceutical Services Inc's WST Q4 net sales increased 26% Y/Y to $730.8 million, beating the consensus of $710.20 million. Organic sales growth was 28.3%.

  • Q4 FY21 EPS reached $2.04 from $1.34 a year ago, surpassing the consensus of $1.91. 
  • Gross profit increased from 36.4% to 41.1%. Adjusted operating profit margin reached 25.9%, up from 20.5% a year ago.
  • "Our performance was fueled by execution across our Proprietary market units and all geographies as we serve to improve patients' lives. Our business generated strong double-digit organic sales growth in the fourth-quarter and full-year 2021, led by sales of high-value products (HVP)," said Eric Green, President & CEO.
  • Proprietary Products Segment sales were up 34.2% to $609.3 million. Organic sales growth was 36.8%.
  • Contract-Manufactured Products Segment revenues declined 3.6% to $121.5 million. Organic sales declined by 2.1%. Consumer products and medical device products led the segment's performance.
  • Operating cash flow was $584.0 million, an increase of 23.6%. 
  • Guidance: West Pharma expects FY22 sales of $3.05 billion - $3.075 billion and reported-diluted EPS of $9.20 to $9.35.
  • Price Action: WST shares closed at $379.32 on Wednesday.
WST Logo
WSTWest Pharmaceutical Services Inc
$203.53-%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
16.19
Growth
26.01
Quality
13.33
Value
48.65
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In: